Skip to Main Content

Hello, everyone, and how are you this fine, sunny morning? The middle of the week has arrived, as you may know, so why not celebrate with a delicious cup of stimulation? After all, you made is this far, which is a likely sign of surviving another few days. And of course, no prescription is required, which is a good thing. And while you drink up, you can peruse some of the tidbits we have assembled to help you start the day. Hope you conquer the world and, as always, do keep in touch …

A federal judge is pushing for a swift resolution to more than 200 lawsuits filed by cities and counties over the opioid crisis, The Wall Street Journal reports. He urged both sides to reach an agreement that involves reducing pills to those who abuse them, rather than just a monetary payment and without enduring the protracted cost and hassle of litigation. “We don’t need briefs and we don’t need trials,” U.S. District Judge Dan Polster said at a Tuesday hearing. “None of those are going to solve what we’ve got.”


GlaxoSmithKline (GSK) chief executive Emma Walmsley would consider buying the Pfizer (PFE) consumer products business, but only if the price were right, Pharmaphorum writes. Pfizer said last year it was considering a sale or spinoff of the unit, which had sales of about $3.4 billion in 2016 and could cost more than $15 billion to acquire. “At this stage it would be weird if we didn’t look at it,” she said, “but we don’t need it and we won’t overpay for it.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!